Your browser is no longer supported. Please, upgrade your browser.
SURF [NASD]
Surface Oncology, Inc.
Index- P/E49.86 EPS (ttm)0.07 Insider Own0.90% Shs Outstand45.24M Perf Week-12.47%
Market Cap167.67M Forward P/E- EPS next Y-1.42 Insider Trans-36.17% Shs Float42.13M Perf Month-31.06%
Income12.90M PEG- EPS next Q-0.15 Inst Own62.30% Short Float4.66% Perf Quarter-53.01%
Sales90.10M P/S1.86 EPS this Y179.10% Inst Trans0.17% Short Ratio3.34 Perf Half Y-43.33%
Book/sh2.90 P/B1.19 EPS next Y-2.20% ROA6.30% Target Price16.75 Perf Year-68.47%
Cash/sh3.07 P/C1.12 EPS next 5Y- ROE8.70% 52W Range3.40 - 12.69 Perf YTD-28.03%
Dividend- P/FCF- EPS past 5Y- ROI34.80% 52W High-73.25% Beta1.61
Dividend %- Quick Ratio9.80 Sales past 5Y- Gross Margin- 52W Low-0.15% ATR0.31
Employees51 Current Ratio9.80 Sales Q/Q- Oper. Margin16.30% RSI (14)25.97 Volatility9.70% 7.65%
OptionableYes Debt/Eq0.00 EPS Q/Q-11.50% Profit Margin14.30% Rel Volume0.99 Prev Close3.44
ShortableYes LT Debt/Eq0.11 Earnings- Payout0.00% Avg Volume587.95K Price3.39
Recom1.50 SMA20-21.27% SMA50-32.19% SMA200-48.33% Volume103,792 Change-1.31%
May-18-21Initiated BTIG Research Buy $17
Sep-04-20Initiated H.C. Wainwright Buy $11
Aug-28-20Initiated Wedbush Outperform $12
Sep-19-18Initiated Robert W. Baird Outperform
May-14-18Initiated Goldman Neutral $17
May-14-18Initiated Evercore ISI Outperform $26
Jan-10-22 01:49PM  
Dec-15-21 07:05AM  
Dec-06-21 09:30AM  
Dec-03-21 07:00AM  
Dec-02-21 07:00AM  
Dec-01-21 07:00AM  
Nov-29-21 06:44AM  
Nov-26-21 06:57AM  
Nov-09-21 08:10AM  
Nov-08-21 03:44PM  
07:00AM  
Nov-04-21 07:10AM  
Nov-02-21 07:00AM  
Oct-12-21 11:21AM  
Oct-04-21 10:56AM  
07:00AM  
Sep-20-21 05:44PM  
Sep-13-21 09:02AM  
Aug-23-21 12:03PM  
Aug-05-21 07:10AM  
Jul-08-21 07:00AM  
07:00AM  
Jun-04-21 10:17AM  
10:04AM  
07:05AM  
07:00AM  
May-28-21 06:20AM  
May-24-21 08:53AM  
May-18-21 08:48AM  
May-16-21 06:20AM  
May-05-21 06:45AM  
Apr-28-21 04:05PM  
Apr-27-21 07:00AM  
Apr-19-21 07:00AM  
Apr-09-21 07:53AM  
Apr-08-21 07:32AM  
Mar-31-21 11:12AM  
Mar-30-21 06:11PM  
04:30PM  
Mar-23-21 11:47PM  
Mar-18-21 08:00AM  
Mar-17-21 08:01AM  
Mar-10-21 04:35PM  
Mar-09-21 08:25AM  
07:01AM  
07:00AM  
06:43AM  
Mar-05-21 08:48AM  
Mar-02-21 12:30PM  
Feb-24-21 07:00AM  
Feb-23-21 07:25AM  
Feb-22-21 06:21AM  
Feb-11-21 07:00AM  
Jan-19-21 03:25PM  
Jan-13-21 08:39AM  
Jan-11-21 06:00AM  
Dec-22-20 12:20PM  
04:37AM  
Dec-17-20 03:35PM  
08:10AM  
06:55AM  
Dec-14-20 07:07AM  
Dec-07-20 08:29AM  
Nov-25-20 07:00AM  
Nov-15-20 08:39AM  
06:57AM  
Nov-13-20 07:05AM  
Nov-11-20 07:00AM  
Nov-10-20 06:20AM  
Nov-09-20 04:25PM  
09:00AM  
Nov-05-20 09:43AM  
Oct-26-20 04:05PM  
Oct-20-20 01:03PM  
Oct-19-20 12:32PM  
Oct-12-20 03:41PM  
Sep-16-20 05:05PM  
Sep-15-20 07:23AM  
Sep-11-20 03:00PM  
Sep-09-20 01:15PM  
Sep-04-20 09:38AM  
Sep-02-20 08:52AM  
Aug-28-20 10:16AM  
Aug-19-20 01:56PM  
Aug-11-20 06:30AM  
Aug-05-20 11:59AM  
Jun-12-20 09:45AM  
Jun-10-20 08:12PM  
May-28-20 04:10PM  
May-20-20 11:28AM  
07:15AM  
07:05AM  
May-15-20 11:46AM  
07:30AM  
May-14-20 07:30AM  
May-13-20 08:00AM  
May-12-20 06:20AM  
May-07-20 12:30PM  
Apr-23-20 08:00AM  
Mar-17-20 08:00AM  
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813, as well as a clinical trial collaboration with Roche Holding AG to evaluate SRF388. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FEES JESSICAChief Financial OfficerJul 21Sale6.1019,854121,10979,329Jan 14 08:30 PM
ONEILL ALISONChief Medical OfficerJul 21Sale6.1014,80990,33530,191Jan 14 08:30 PM
Nogelo Liisa IChief Legal OfficerJul 21Sale6.1026,325160,58253,675Jan 14 08:30 PM
ROSS ROBERT W.Chief Executive OfficerJul 21Sale6.1033,500204,35054,500Jan 14 08:30 PM
Palombella Vito J.Chief Scientific OfficerJul 21Sale6.1026,325160,58253,675Jan 14 08:30 PM
Goater JeffDirectorJul 21Sale6.10127,778779,446129,222Jan 14 08:30 PM
Goater JeffDirectorJun 11Option Exercise4.1410,27342,530272,273Jun 11 08:30 PM
Goater JeffDirectorJun 11Sale7.6115,273116,226257,000Jun 11 08:30 PM
Goater JeffDirectorJun 10Option Exercise4.14234,727971,770496,727Jun 11 08:30 PM
Goater JeffDirectorJun 10Sale7.66234,7271,798,619262,000Jun 11 08:30 PM
ROSS ROBERT W.Chief Medical OfficerFeb 16Sale11.351,00011,35088,000Feb 18 08:00 PM
Goater JeffChief Executive OfficerFeb 08Option Exercise3.182,5007,950264,500Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 08Sale12.502,50031,250262,000Feb 09 08:00 PM
FEES JESSICASee RemarksFeb 08Sale12.451,50018,67599,183Feb 09 08:00 PM
Goater JeffChief Executive OfficerFeb 01Option Exercise3.182,5007,950264,500Feb 03 08:00 PM
FEES JESSICASee RemarksFeb 01Sale11.191,50016,785100,683Feb 03 08:00 PM
Goater JeffChief Executive OfficerFeb 01Sale10.692,50026,718262,000Feb 03 08:00 PM